Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Deep Apple Therapeutics
United States
- San Francisco Bay Area
- 18/12/2023
- Series A
- $52,000,000
In a vast, unexplored virtual chemical space, Deep Apple Therapeutics moves with unprecedented speed to discover novel small molecules for high-value targets. Deep Apple combines ensemble cryo-EM to explore receptor conformations; deep learning; and the docking of multi-billion compound libraries generated using the company's proprietary Orchard.ai™ algorithm. Deep Apple's deep learning discovery engine is built upon founder expertise in computational modeling, protein and target structure determination, large-scale molecular docking, and the elucidation of protein dynamics and conformational transitions. This structure-based, machine-learning driven drug design approach enables the company to rapidly advance novel candidates addressing well-validated targets in inflammatory, metabolic, and endocrine diseases. For more information, visit deepappletx.com.
- Industry Biotechnology Research
- Website https://deepappletx.com/
- LinkedIn https://www.linkedin.com/company/deep-apple-therapeutics/about/
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)